Landkind Announces Preliminary Results from ISTO Clinical Study Showing LK-01™ Pure Salidroside Supports Oxygen Uptake and Mood state
January 05, 2023 09:00 ET
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023 06:58 ET
|
Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
January 03, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through...
Landkind reaches significant regulatory milestone, achieving GRAS status for LK-01™ Pure Salidroside
December 19, 2022 08:00 ET
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
December 15, 2022 06:59 ET
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
November 30, 2022 16:15 ET
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications
November 28, 2022 09:41 ET
|
DoubleRainbow Biosciences
Lexington, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health,...
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 06:59 ET
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Synthetic Biology Global Market Report 2022: Extensive Applications Of Synthetic Biology Drive Sector Growth
November 08, 2022 08:43 ET
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Synthetic Biology Market Size, Share & Trends Analysis Report by Product (Enzymes, Cloning Technologies Kits), by Technology (PCR, NGS), by...
DoubleRainbow Biosciences Announces Strategic AI Collaboration with Galixir
November 07, 2022 08:10 ET
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Double Rainbow, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human...